Atara Biotherapeutics Inc. (NASDAQ:ATRA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. “

A number of other analysts have also recently commented on ATRA. JMP Securities restated a “buy” rating on shares of Atara Biotherapeutics in a report on Saturday, July 9th. Canaccord Genuity restated a “buy” rating on shares of Atara Biotherapeutics in a report on Tuesday, June 7th. Jefferies Group restated a “buy” rating and set a $25.00 target price on shares of Atara Biotherapeutics in a report on Tuesday, August 9th. Goldman Sachs Group Inc. cut shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and dropped their target price for the company from $23.00 to $16.00 in a report on Thursday, September 15th. Finally, Citigroup Inc. boosted their target price on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a report on Friday, August 19th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $26.14.

Shares of Atara Biotherapeutics (NASDAQ:ATRA) opened at 19.17 on Friday. The stock’s market cap is $552.31 million. The company’s 50-day moving average is $21.49 and its 200-day moving average is $19.99. Atara Biotherapeutics has a 12-month low of $13.31 and a 12-month high of $45.91.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Monday, August 8th. The company reported ($0.66) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.05. On average, equities research analysts anticipate that Atara Biotherapeutics will post ($2.85) earnings per share for the current year.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 9,600 shares of the company’s stock in a transaction dated Friday, June 24th. The shares were sold at an average price of $21.26, for a total transaction of $204,096.00. Following the transaction, the chief executive officer now owns 223,228 shares in the company, valued at approximately $4,745,827.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Isaac E. Ciechanover sold 7,200 shares of the company’s stock in a transaction dated Friday, September 16th. The shares were sold at an average price of $19.36, for a total transaction of $139,392.00. Following the transaction, the chief executive officer now owns 229,136 shares in the company, valued at approximately $4,436,072.96. The disclosure for this sale can be found here. 16.10% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the stock. BlackRock Group LTD boosted its position in Atara Biotherapeutics by 76.8% in the first quarter. BlackRock Group LTD now owns 5,400 shares of the company’s stock valued at $103,000 after buying an additional 2,345 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in Atara Biotherapeutics by 6.9% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 417,248 shares of the company’s stock valued at $7,940,000 after buying an additional 26,860 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Atara Biotherapeutics by 3.1% in the first quarter. JPMorgan Chase & Co. now owns 62,600 shares of the company’s stock valued at $1,191,000 after buying an additional 1,900 shares in the last quarter. RTW Investments LLC boosted its position in Atara Biotherapeutics by 11.1% in the first quarter. RTW Investments LLC now owns 473,126 shares of the company’s stock valued at $9,004,000 after buying an additional 47,274 shares in the last quarter. Finally, A.R.T. Advisors LLC boosted its position in Atara Biotherapeutics by 79.6% in the first quarter. A.R.T. Advisors LLC now owns 63,941 shares of the company’s stock valued at $1,216,000 after buying an additional 28,330 shares in the last quarter. Institutional investors and hedge funds own 75.50% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.